Mercury Laboratories Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Mercury Laboratories Ltd is ₹ 755.05 as of 12 May 15:30 . The P/E Ratio of Mercury Laboratories Ltd is 0 as of March 2021 .The P/E Ratio of Novelix Pharmaceuticals Ltd is 0 as of March 2021 . The Market Cap of Mercury Laboratories Ltd is ₹ 0 crore as of March 2021 .The Market Cap of Novelix Pharmaceuticals Ltd is ₹ 5.48 crore as of March 2021 . The revenue of Mercury Laboratories Ltd for the Dec '25 is ₹ 18.66 crore as compare to the Sep '25 revenue of ₹ 19.8 crore. This represent the decline of -5.76% The revenue of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 48.4 crore as compare to the Sep '25 revenue of ₹ 36.39 crore. This represent the growth of 33% The ebitda of Mercury Laboratories Ltd for the Dec '25 is ₹ 2.44 crore as compare to the Sep '25 ebitda of ₹ 2.92 crore. This represent the decline of -16.44% The ebitda of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 1.31 crore as compare to the Sep '25 ebitda of ₹ 0.73 crore. This represent the growth of 79.45% The net profit of Mercury Laboratories Ltd changed from ₹ 0.34 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of 85.24% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ -0.35 crore to ₹ 1 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Mercury Laboratories Ltd changed from 7.87 % on March 2021 to 13.38 % on March 2025 . This represents a CAGR of 11.20% over 5 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Mercury Laboratories Ltd

Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
Subsequently, it converted into Private Limited Company & incorporated in February, 1982.
Later, it converted into Limited Company in 1992 in Maharashtra.
The Company has obtained ISO 9001:2008 registrations.
It is engaged into the manufacturing and export of wide range of Pharmaceutical items.

About Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Limited was initially incorporated as 'Trimurthi Securities Limited' on December 13, 1994.
The name of the Company was changed from Trimurthi Securities Limited to Trimurthi Drugs & Pharmaceuticals Limited.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Limited and again to Trimurthi Limited in May, 2016.
The Company has altered the name to Novelix Pharmaceuticals Limited in 2025. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.

FAQs for the comparison of Mercury Laboratories Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Mercury Laboratories Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Mercury Laboratories Ltd is 90 Cr while Market cap of Novelix Pharmaceuticals Ltd is 58 Cr

What are the key factors driving the stock performance of Mercury Laboratories Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Mercury Laboratories Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mercury Laboratories Ltd and Novelix Pharmaceuticals Ltd?

As of May 12, 2026, the Mercury Laboratories Ltd stock price is INR ₹755.05. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹40.5.

How do dividend payouts of Mercury Laboratories Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Mercury Laboratories Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.